Theravance Biopharma (TBPH) Finished Goods (2013 - 2018)

Theravance Biopharma (TBPH) has reported Finished Goods for 6 consecutive years, with $3.5 million the latest figure, recorded in Q3 2018.

• In Q3 2018, Finished Goods fell 22.92% year-over-year to $3.5 million; the TTM figure through Sep 2018 stood at $3.5 million (down 22.92% YoY), while the FY2017 annual figure was $5.0 million, up 42.8% from the prior year.
• Finished Goods fell to $3.5 million in Q3 2018 per TBPH's latest filing, from $4.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $7.5 million in Q3 2014 and bottomed at $2.0 million in Q2 2017.
• Historically, Finished Goods has averaged $4.3 million across 5 years, with a median of $4.6 million in 2017.
• Annual changes were most pronounced in 2016 — Finished Goods slumped 58.75% — and 2018, when it soared 99.6%.
• Theravance Biopharma's Finished Goods stood at $5.6 million in 2014, then slumped by 43.71% to $3.1 million in 2015, then climbed by 12.44% to $3.5 million in 2016, then surged by 42.8% to $5.0 million in 2017, then sank by 30.29% to $3.5 million in 2018.
• Business Quant data shows TBPH's Finished Goods at $3.5 million in Q3 2018, $4.0 million in Q2 2018, and $4.6 million in Q1 2018.